Straight out of janssens incivo booklet
http://www.medhelp.org/user_photos/show/308364?personal_page_id=2257209
http://www.hepcnomads.co.uk/Incivo/Diet_and_Lifestyle_Booklet_incivo.pdf
Wow....40 posts on what to take Inci with ?
Possibly try 20 grams of fat for best results. (as per instuctions) as HPG has said...
Will
I guess anything is worth a shot, but if you fail with these drugs, you can't just go back and follow the instructions :) So my advice to all is to follow the instructions.
Have a great day
FYI, Me taking the pills with whole milk was not that I took a "risk" or just got lucky. This came from a leading Hepatologist in Boston. I wasn't able to keep the pills down with fat. Taking with milk was an "alternative" that worked.
I'm not suggesting for anyone to take with just milk. But rather then not taking them at all you can drink milk instead.
Actually with this resilient virus I will take some luck as well :-)
Yep, this one is from 2012, not sure why they needed to repeat it (and they do have different results as well, lower than the ones you have posted and probably morea realistic. Still, 74% is good :)
Janssen Research & Development Infectious Diseases - Diagnostics BVBA (Janssen) will present results from the OPTIMIZE Phase 3 trial for INCIVO® (telaprevir), during a late-breaking poster presentation at the 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston (http://www.aasld.org/lm2012). The study, which was completed in September, investigates the efficacy and safety of the twice-daily dosing (BID) of telaprevir versus dosing every eight hours (q8h) in people chronically infected with genotype-1 hepatitis C virus (HCV) who had not been previously treated.[1]
The results demonstrated that BID dosing of telaprevir 1,125mg in combination with peginterferon alfa and ribavirin (PR), achieved similar cure rates, also known as sustained virological response (SVR12) to q8h dosing of telaprevir 750mg (74.3% versus 72.8%), thereby meeting its primary objective of non-inferiority versus q8h dosing.[1] The safety and tolerability of telaprevir was comparable across dosing arms and consistent with previous studies. The most common adverse events experienced were fatigue, pruritus, anemia, nausea and rash.[
Study C208 explored telaprevir-based regimens dosed either every 12 hours (q12h; twice daily) or every eight hours (q8h; three times daily) combined with either peg-IFN-alfa-2a (PEGASYS(R)) or peg-IFN-alfa-2b (PEGINTRON(R)) and ribavirin (RBV), for 12 weeks followed by an additional 12 weeks of peg-IFN and RBV in a response-guided trial design that included 161 treatment-naïve patients (intent-to-treat analysis) with genotype 1 hepatitis C virus (HCV) infection. Across the four arms, SVR rates were 82 and 83 percent in patients treated with the every 12 hour telaprevir-based regimen (PEGINTRON and PEGASYS, respectively) and 81 and 85 percent in patients treated with the every 8 hour regimen (PEGINTRON and PEGASYS, respectively). For the majority of patients, these SVR rates were obtained with a 24-week telaprevir-based regimen.
"With high SVR rates and similar safety outcomes between the twice-daily and three-times-daily treatment groups, the results from this exploratory study support the future evaluation of telaprevir-based regimens dosed twice daily," said Professor Patrick Marcellin, M.D., from Beaujon Hospital in Clichy, France. "These results also highlight the potential future role for response-guided therapy with the goal of improving treatment outcomes and potentially shortening the duration of therapy for the majority of patients."
Study C208 Results RVR* SVR**
TVR (q12h/peg-IFN alfa-2a/RBV) (n=40) 83% (n=33) 83% (n=33)
TVR (q12h/peg-IFN alfa-2b/RBV) (n=39) 67% (n=26) 82% (n=32)
TVR (q8h/peg-IFN alfa-2a/RBV) (n=40) 80% (n=32) 85% (n=34)
TVR (q8h/peg-IFN alfa-2b/RBV) (n=42) 69% (n=29) 81% (n=34)
* Rapid Viral Response: Undetectable HCV RNA at week 4
** Sustained Viral Response: Undetectable HCV RNA 24 weeks after the end of treatment
alfa-2a: PEGASYS
alfa-2b: PEGINTRON
(cont) at the following link
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=420611